Development and Characterization of a Novel Carbon-11 Labeled Positron Emission Tomography Radiotracer for Neuroimaging of Sirtuin 1 with Benzoxazine-Based Compounds
Yanli Wang,Yan Liu,Yongle Wang,Ping Bai,Madelyn Rose Hallisey,Breanna Varela,Anne Siewko,Changning Wang,Yulong Xu
DOI: https://doi.org/10.2147/dddt.s439589
IF: 4.3188
2024-03-15
Drug Design Development and Therapy
Abstract:Yanli Wang, 1 Yan Liu, 1, 2 Yongle Wang, 1, 3 Ping Bai, 1 Madelyn Rose Hallisey, 1 Breanna Lizeth Varela, 1 Anne Siewko, 1 Changning Wang, 1 Yulong Xu 1 1 Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA; 2 School of Pharmacy, Lanzhou University, Lanzhou, Gansu, 730000, People's Republic of China; 3 School of Pharmacy, Minzu University of China, Beijing, 100081, People's Republic of China Correspondence: Yulong Xu; Changning Wang, Email ; Introduction: Sirtuins (SIRTs) comprise a group of histone deacetylase enzymes crucial for regulating metabolic pathways and contributing significantly to various disease mechanisms. Sirtuin 1 (SIRT1), among the seven known mammalian homologs, is extensively investigated and understood, playing a key role in neurodegenerative disorders and cancer. This study focuses on potential as a therapeutic target for conditions such as Parkinson's disease (PD), Huntington's disease (HD), and Alzheimer's disease (AD). Methods: Utilizing positron emission tomography (PET) as a noninvasive molecular imaging modality, we aimed to expedite the validation of a promising sirtuin 1 inhibitor for clinical trials. However, the absence of a validated sirtuin 1 PET radiotracer impedes clinical translation. We present the development of [ 11 C] 1 , and 11 C-labeled benzoxazine-based derivative, as a lead imaging probe. The radiosynthesis of [ 11 C] 1 resulted in a radiochemical yield of 31 ± 4%. Results: Baseline studies demonstrated that [ 11 C] 1 exhibited excellent blood-brain barrier (BBB) penetration capability, with uniform accumulation throughout various brain regions. Self-blocking studies revealed that introducing an unlabeled compound 1 , effectively blocking sirtuin 1, led to a substantial reduction in whole-brain uptake, emphasizing the in vivo specificity of [ 11 C] 1 for sirtuin 1. Discussion: The development of [ 11 C] 1 provides a valuable tool for noninvasive imaging investigations in rodent models with aberrant sirtuin 1 expression. This novel radiotracer holds promise for advancing our understanding of sirtuin 1's role in disease mechanisms and may facilitate the validation of sirtuin 1 inhibitors in clinical trials. Keywords: sirtuin 1, neuroimaging, benzoxazine-based derivative, blood-brain barrier Sirtuins, as nicotinamide adenine dinucleotide (NAD + )-dependent deacetylases, play a pivotal role in deacetylating diverse protein substrates, including transcription factors and histones. 1 The broad involvement of sirtuins in numerous physiological processes highlights their significant biological relevance. Within the sirtuin family, comprised of seven known members (sirtuin 1–7), each subtype exhibits distinct localization and functions. Notably, sirtuin 1 has garnered substantial attention over the past two decades, primarily due to its association with increased longevity. 2 Extensive evidence suggests that sirtuin 1 plays a role in normal cell development, inflammatory responses, and energy metabolism, making it a potential therapeutic target for addressing age-related diseases, including neurodegenerative disorders and cancer. 3–5 To date, various chemical modulators targeting sirtuin 1 have been developed, encompassing both activators and inhibitors. Sirtuin 1 (SIRT1) activators and inhibitors employ distinct mechanisms to modulate the activity and function of the SIRT1 enzyme. Activators enhance SIRT1's enzymatic activity by interacting with the enzyme, thereby increasing its binding affinity to substrates such as histones and other proteins. Additionally, some activators may induce the upregulation of SIRT1 expression, resulting in elevated enzyme levels. These actions contribute to physiological benefits, including improved metabolic function and potential longevity. Conversely, SIRT1 inhibitors suppress the enzymatic activity of SIRT1 by binding to its catalytic site, preventing the deacetylation of target proteins. The dynamic regulation of the SIRT1 enzyme by both activators and inhibitors influences various cellular pathways and processes in a context-dependent manner. 6 Sirtuin 1 activators, such as resveratrol and SRT1720, have demonstrated protective effects against conditions like diabetes, obesity-induced fatty liver, and insulin resistance. Nonetheless, several limitations hinder the practical applications of these activat -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal